Vir Biotechnology (VIR) EBITDA (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of EBITDA data on file, last reported at -$132.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 5.2% year-over-year to -$132.3 million; the trailing twelve-month figure through Mar 2026 stood at -$472.1 million (up 27.0% YoY), and the FY2025 full-year result was -$479.3 million, up 18.37% from the prior year.
• EBITDA retreated to -$132.3 million in Q1 2026, from -$47.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.0 billion in Q1 2022 to a low of -$231.3 million in Q3 2024.
• A 5-year average of -$61.8 million and a median of -$139.5 million in 2025 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 739.1% in 2022, while the deepest fall reached 469.11% in 2022.
• Tracing VIR's EBITDA over 5 years: stood at -$150.5 million in 2022, then increased by 7.63% to -$139.0 million in 2023, then climbed by 15.73% to -$117.2 million in 2024, then surged by 59.09% to -$47.9 million in 2025, then slumped by 176.06% to -$132.3 million in 2026.
• Business Quant data shows VIR's EBITDA at -$132.3 million in Q1 2026, -$47.9 million in Q4 2025, and -$173.4 million in Q3 2025.